CLINICAL TRIALS PROFILE FOR VASCOR
✉ Email this page to a colleague
All Clinical Trials for VASCOR
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05943821 ↗ | The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With Cardiovascular Risk | Recruiting | Poznan University of Medical Sciences | Phase 3 | 2023-09-01 | Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk, excluding ischemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of death. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VASCOR
Condition Name
Clinical Trial Locations for VASCOR
Clinical Trial Progress for VASCOR
Clinical Trial Phase
Clinical Trial Sponsors for VASCOR
Sponsor Name